Valutazione economica dell’incremento della copertura vaccinale contro la pertosse in Toscana: una nota preliminare
Economic evaluation of increased vaccination coverage against pertussis in Tuscany: a preliminary study
Objective: To validate a previously performed cost-benefit analysis of acellular pertussis vaccination with data collected ‘on the field’ in Tuscany.
Design: Empirical economic analysis based on the collection of epidemiological and economic data from different databases and medical sources in Tuscany. Incremental health and economic outcomes were calculated for each year relative to the previous one, from 1994 to 1999. Comparisons were also made between years of low (1994–96) versus high (1997–99) vaccination coverage against pertussis.
Setting: Tuscany Region, an Italian area with a population of about 3.5 million, and a vaccination coverage against pertussis of about 95% in 1999.
Main outcome measures and results: Analysis of data from Tuscany substantially confirmed the important savings (a direct net saving of € 31 and a total net saving of € 41 per additional vaccinee) associated with increased pertussis vaccination coverage that had been forecasted by the model. With the exception of the years 1995 and 1998 (when expenditure raised sharply due to a much higher vaccine consumption), all other years showed economic benefits associated with increased vaccination coverage. More importantly, vaccination is expected to show its full benefits in the next few years.
Conclusions: Considering the trend towards recommended-only vaccinations in Italy, the costs of campaigns aimed at informing and educating the Italian population about the benefits of immunisation are well worth being sustained also from an economic point of view. As shown by our study, high vaccination coverage against pertussis appears to be associated with remarkable savings.
Unable to display preview. Download preview PDF.
- 1.The Italian Vaccine Coverage Survey Working Group. Childhood vaccination coverage in Italy: results of a seven-region survey. Bull WHO 1994; 72: 885–95Google Scholar
- 2.Ministero della Sanità. Circolare 6 giugno 1995, n. 13: Esecuzione delle vaccinazioni obbligatorie e facoltative in attuazione del Piano Sanitario Nazionale 1994–96Google Scholar
- 8.Biagini R, Bonaccorsi G, Isola A, et al. Due casi di tetano nel territorio della Valdinievole: come e perché possono ancora verificarsi episodi di una malattia di classe prima evitabile mediante intervento vaccinale. Atti della Sezione Toscana della SItI — Seduta Scientifica 15/11/1996, 1997: 55–62Google Scholar
- 12.Blumberg DA, Mink CM. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. J Pediatr 1991; 1: 119–94Google Scholar
- 14.Englund JA, Edwards K, MacDonald PD. Multicenter study of acellular (AC) and whole-cell (WC) pertussis vaccines in young children. Program and abstracts 1991; 10Google Scholar
- 21.Kanra G, Ruuskanen O, Burnie JP. 69 kDa in acellular DTP vaccine: safety in adults and booster in 18-month old children. Program and abstracts 1991; 109Google Scholar
- 26.Rothstein E, Bernstein H, Kimura M. Comparison of a 3-component acellular pertussis vaccine (DTwp) in 4–6 year old children. An annual meeting of the American Society for Microbiology 1992: 305Google Scholar
- 27.Schmitt HJ, Muller F, Zell ER, et al. Safety and immunogenicity of bicomponent and tricomponent acellular pertussis DTP vaccines in infants. Program and Abstracts 1992; 14: 275Google Scholar
- 28.Consiglio Nazionale Economia e Lavoro (CNEL). La retribuzione dei lavoratori dipendenti italiani. Fogli di informazione (CGIL), 1990.Google Scholar
- 29.Lucioni C, Ciriminna S, Di Carlo P, et al. Il costo sociale del morbillo in età pediatrica: l’epidemia a Palermo nel 1996–97. PharmacoEconomics — Italian Research Articles 1999; 1: 17–33Google Scholar